Dr. Peter Georges, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 363
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NH license 18662 · NJ license 25MA09130900 -
Internal Medicine Physician
MA license 242582
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Hitchcock Memorial Hospital Lebanon, NH
- Wentworth-Douglass Hospital Dover, NH
- Elliot Hospital Manchester, NH
- Catholic Medical Center Manchester, NH
- York Hospital York, ME
Medical groups
- Mary Hitchcock Memorial Hospital (1,280 clinicians)
- Wentworth Douglass Physician Corporation (429 clinicians)
- York Hospital (198 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 363
- Services billed
- 822
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 702 | 220 |
| Established patient office or other outpatient visit, 20-29 minutes | 212 | 141 |
| New patient office or other outpatient visit, 60-74 minutes | 53 | 53 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 49 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 38 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 40-54 minutes | 13 | 13 |
| Hospital discharge day management, more than 30 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Camden, NJ | 56 |
| Anastrozole Other prescribers in Camden, NJ | 49 |
| Prednisone Other prescribers in Camden, NJ | 35 |
| Xarelto (rivaroxaban) Other prescribers in Camden, NJ | 33 |
| Prochlorperazine Maleate Other prescribers in Camden, NJ | 32 |
| Levothyroxine Sodium Other prescribers in Camden, NJ | 27 |
| Xtandi (enzalutamide) | 27 |
| Acyclovir Other prescribers in Camden, NJ | 27 |
| Pomalyst (pomalidomide) | 24 |
| Revlimid (lenalidomide) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 20 payments worth $16,832 in total to this clinician.
| GlaxoSmithKline, LLC. | $7,357 |
|---|---|
| Incyte Corporation | $2,365 |
| Pfizer Inc. | $2,100 |
| AbbVie Inc. | $1,845 |
| AstraZeneca Pharmaceuticals LP | $1,675 |
| Janssen Scientific Affairs, LLC | $1,180 |
| Astellas Pharma US Inc | $155 |
| Genmab U.S., Inc. | $99.91 |
| Consulting Fee | $11,658 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,715 |
| Food and Beverage | $460 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee OJJAARA · ONCOLOGY | $2,538 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| AbbVie Inc. Jan 28, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,800 |
| AstraZeneca Pharmaceuticals LP May 11, 2025 | Consulting Fee | $1,675 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee | $1,505 |
| GlaxoSmithKline, LLC. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,452 |
| Janssen Scientific Affairs, LLC May 27, 2025 | Consulting Fee | $880 |
| Incyte Corporation Jun 11, 2025 | Consulting Fee | $860 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $363 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $363 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Janssen Scientific Affairs, LLC Aug 15, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee | $1,505 |
| Incyte Corporation Jun 11, 2025 | Consulting Fee | $860 |
| Janssen Scientific Affairs, LLC May 27, 2025 | Consulting Fee | $880 |
| AstraZeneca Pharmaceuticals LP May 11, 2025 | Consulting Fee | $1,675 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee OJJAARA · ONCOLOGY | $2,538 |
| AbbVie Inc. Jan 28, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,800 |
| Janssen Scientific Affairs, LLC Jan 17, 2025 | Consulting Fee TALVEY · Oncology | $150 |
| GlaxoSmithKline, LLC. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,452 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.